Skip to main content
SpringerLink
Log in

Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials

  • Meta-Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

An Erratum to this article was published on 12 September 2014

Abstract

It is not known whether low-dose radioiodine is as effective as high-dose radioiodine for treating patients with differentiated thyroid cancer after surgery. This study compared ablation success rates of different doses of radioiodine in patients with differentiated thyroid cancer after thyroidectomy. Fifteen randomized controlled trials were obtained from PubMed, Embase, and Cochrane Library (1966 to February 2013). Stata version 12.0 was used to pool the outcomes. Mantel–Haenszel (MH) and inverse variance (IV) methods were used in a fixed-effects and random-effects model, respectively. The relative risk (RR) with 95 % confidence interval (CI) was used to compare the success rates of different doses of radioiodine. There were a total of 3,046 patients. The pooled RR for comparing ablation success with low- and high-dose radioiodine was 0.90 (95 % CI 0.83–0.98, IV). Excluding a study with a distinctive outcome, sensitivity analysis showed that the pooled RR was 0.95 (95 % CI 0.92–0.99, MH). In subgroup analysis, the pooled RR of three studies that only administrated radioiodine to patients with pT2–4 cancer was 0.93 (95 % CI 0.83–1.04, MH); the pooled RR of five studies with total thyroidectomy for all patients was 0.96 (95 % CI 0.92–1.00, MH); and the pooled RR of four studies that used thyrotropin α to stimulate serum thyrotropin was 0.96 (95 % CI 0.90–1.02, MH). The pooled RRs for comparing ablation success for moderate-dose versus high-dose and low-dose radioiodine were 0.94 (95 % CI 0.85–1.04, IV) and 0.87 (95 % CI 0.73–1.04, IV), respectively. Low-dose radioiodine can be used in patients undergoing total thyroidectomy. For those who receive insufficient surgical treatment, high-dose radioiodine is more appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668–3676 (2004). doi:10.1210/jc.2003-031167

    Article  CAS  PubMed  Google Scholar 

  2. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS. Med. 6(7), e1000097 (2009). doi:10.1371/journal.pmed.1000097

    Article  PubMed Central  PubMed  Google Scholar 

  3. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011). doi:10.1136/bmj.d5928

    Article  Google Scholar 

  4. U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol, P.M. Clark, K. Farnell, R. McCready, J. Smellie, J.A. Franklyn, R. John, C.M. Nutting, K. Newbold, C. Lemon, G. Gerrard, A. Abdel-Hamid, J. Hardman, E. Macias, T. Roques, S. Whitaker, R. Vijayan, P. Alvarez, S. Beare, S. Forsyth, L. Kadalayil, A. Hackshaw, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366(18), 1674–1685 (2012). doi:10.1056/NEJMoa1109589

    Article  CAS  PubMed  Google Scholar 

  5. M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy, C. Bournaud, F. Bonichon, C. Dejax, M.E. Toubert, S. Leboulleux, M. Ricard, E. Benhamou, Tumeurs de la thyroide refractaires network for the essai stimulation ablation equivalence, t.: strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366(18), 1663–1673 (2012). doi:10.1056/NEJMoa1108586

    Article  CAS  PubMed  Google Scholar 

  6. Sirisalipoch, S., Buachum, V., Pasawang, P., Tepmongkol, S.: Prospective randomised trial for the evaluation of the efficacy of low vs. high dose I-131 for post operative remnant ablation in differentiated thyroid cancer. World J. Nucl. Med. 3(suppl. 1) (2004)

  7. T. Pilli, E. Brianzoni, F. Capoccetti, M.G. Castagna, S. Fattori, A. Poggiu, G. Rossi, F. Ferretti, E. Guarino, L. Burroni, A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92(9), 3542–3546 (2007)

    Article  CAS  PubMed  Google Scholar 

  8. M. Zaman, R. Toor, S. Kamal, M. Maqbool, S. Habib, K. Niaz, A randomized clinical trial comparing 50 mCi and 100 mCi of iodine-131 for ablation of differentiated thyroid cancers. J. Pak. Med. Assoc. 56(8), 353–356 (2006)

    PubMed  Google Scholar 

  9. M. Caglar, F.M. Bozkurt, C.K. Akca, S.E. Vargol, M. Bayraktar, O. Ugur, E. Karaagaoglu, Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl. Med. Commun. 33(3), 268–274 (2012). doi:10.1097/MNM.0b013e32834ec5d6

    Article  CAS  PubMed  Google Scholar 

  10. M. Gawkowska-Suwinska, M. Turska, J. Roskosz, Z. Puch, B. Jurecka-Tuleja, D. Handkiewicz-Junak, Z. Wygoda, B. Jarzab, Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad. Lek. 54(Suppl 1), 278–288 (2001)

    PubMed  Google Scholar 

  11. C. Bal, A.K. Padhy, S. Jana, G.S. Pant, A.K. Basu, Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77(12), 2574–2580 (1996). doi:10.1002/(SICI)1097-0142(19960615)77:12<2574:AID-CNCR22>3.0.CO;2-O

    Article  CAS  PubMed  Google Scholar 

  12. H. Creutzig, High or low dose radioiodine ablation of thyroid remnants? Eur. J. Nucl. Med. 12(10), 500–502 (1987)

    Article  CAS  PubMed  Google Scholar 

  13. K. Johansen, N.J. Woodhouse, O. Odugbesan, Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J. Nucl. Med. 32(2), 252–254 (1991)

    CAS  PubMed  Google Scholar 

  14. H.O. Maenpaa, J. Heikkonen, L. Vaalavirta, M. Tenhunen, H. Joensuu, Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS. One. 3(4), e1885 (2008). doi:10.1371/journal.pone.0001885

    Article  PubMed Central  PubMed  Google Scholar 

  15. B. Fallahi, D. Beiki, A. Takavar, A. Fard-Esfahani, K.A. Gilani, M. Saghari, M. Eftekhari, Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl. Med. Commun. 33(3), 275–282 (2012). doi:10.1097/MNM.0b013e32834e306a

    Article  CAS  PubMed  Google Scholar 

  16. C. Bal, P. Chandra, A. Kumar, S. Dwivedi, A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. Nucl. Med. Commun. 33(10), 1039–1047 (2012). doi:10.1097/MNM.0b013e32835674af

    Article  CAS  PubMed  Google Scholar 

  17. C.S. Bal, A. Kumar, G.S. Pant, Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J. Clin. Endocrinol. Metab. 89(4), 1666–1673 (2004)

    Article  CAS  PubMed  Google Scholar 

  18. A. Kukulska, J. Krajewska, J. Roskosz, D. Handkiewicz-Junak, M. Jarzab, E. Paliczka, Z. Puch, Z. Wygoda, E. Gubala, B. Jarzab, Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi. Endokrynol. Pol. 57(4), 374–379 (2006)

    PubMed  Google Scholar 

  19. A. Hackshaw, C. Harmer, U. Mallick, M. Haq, J.A. Franklyn, 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J. Clin. Endocrinol. Metab. 92(1), 28–38 (2007). doi:10.1210/jc.2006-1345

    Article  CAS  PubMed  Google Scholar 

  20. H. Maxon 3rd, E.E. Englaro, S.R. Thomas, V.S. Hertzberg, J.D. Hinnefeld, L. Chen, H. Smith, D. Cummings, M.D. Aden, Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J. Nucl. Med. 33(6), 1132 (1992)

    PubMed  Google Scholar 

  21. S.A. Doi, N.J. Woodhouse, Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin. Endocrinol. 52(6), 765–773 (2000)

    Article  CAS  Google Scholar 

  22. W. Cheng, C. Ma, H. Fu, J. Li, S. Chen, S. Wu, H. Wang, Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J. Clin. Endocrinol. Metab. 98(4), 1353–1360 (2013). doi:10.1210/jc.2012-3682

    Article  CAS  PubMed  Google Scholar 

  23. N.G. Iyer, L.G. Morris, R.M. Tuttle, A.R. Shaha, I. Ganly, Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117(19), 4439–4446 (2011). doi:10.1002/cncr.26070

    Article  PubMed Central  PubMed  Google Scholar 

  24. C. Rubino, F. de Vathaire, M.E. Dottorini, P. Hall, C. Schvartz, J.E. Couette, M.G. Dondon, M.T. Abbas, C. Langlois, M. Schlumberger, Second primary malignancies in thyroid cancer patients. Br. J. Cancer 89(9), 1638–1644 (2003). doi:10.1038/sj.bjc.6601319

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. A.F. Esfahani, B. Fallahi, R. Olamaie, M. Eftekhari, D. Beiki, M. Saghari, Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment. Hell. J. Nucl. Med. 7(3), 206–209 (2004)

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of General Surgery, Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China

    Peizhun Du, Xuelong Jiao, Yanbing Zhou & Yu Li

  2. Department of Epidemiology and Health Statistics, The Medical College of Qingdao University, Qingdao, China

    Shan Kang & Dongfeng Zhang

  3. Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People’s Hospital, Beijing, China

    Jizhun Zhang & Liang Lv

Authors
  1. Peizhun Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuelong Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanbing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shan Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dongfeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jizhun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanbing Zhou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, P., Jiao, X., Zhou, Y. et al. Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials. Endocrine 48, 96–105 (2015). https://doi.org/10.1007/s12020-014-0333-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0333-8

Keywords

Search

Navigation